Arca
Skip to content
Tools
Tools

Retinoblastoma

Drug research and approvals for retinoblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 22 studies of retinoblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 8 open orphan designations naming it.

  • Recruiting worldwide: 22
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 22 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 8

Phase 2 6

Phase 1 or earlier 2

How its trials ended

121 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 23 whose ending is known, 13% met their primary endpoint, 0% missed it and 87% stopped early.

  • Completed, result not reported4638%
  • Ongoing3630%
  • Status unknown1613%
  • Stopped: enrollment or feasibility97%
  • Stopped: other or unclear87%
  • Met its primary endpoint32%
  • Stopped: sponsor or business decision22%
  • Stopped: lack of efficacy11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 9, 2022Intravitreal melphalan for intraocular retinoblastomaMelphalan / Etoposide phosphateChildrens Oncology GroupOngoing
Oct 15, 2020A phase I study of sequestered transscleral, controlled-release topotecan delivered from an episcleral reservoir in unilateral group d retinoblastoma eyesEpiscleral topotecanTargeted Therapy Technologies, LLCPending
Apr 22, 2020Phase I sustained-release topotecan episcleral plaque (chemoplaque) for retinoblastoma (step-rb)TopotecanThe Hospital for Sick ChildrenClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 24, 2025MelphalanTreatment of retinoblastomaZhaoke OphthalmologyDesignated
Jul 29, 2024TopotecanTreatment of retinoblastomaLumentra Therapeutics Inc.Designated
Feb 7, 2022Genetically modified human adenovirus encoding human PH20Treatment of RetinoblastomaVCN Biosciences S.L.Designated
Nov 24, 2020Murine double minute-2 (MDM2) or Human double minute-2…Treatment of RetinoblastomaAscentage Pharma Group Inc.Designated
Sep 14, 2020N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-tr…Treatment of retinoblastomaOxular LtdDesignated
Jul 24, 2019Episcleral TopotecanTreatment of retinoblastomaTargeted Therapy Technologies, LLC., DBA: 3T OphthalmicsDesignated
Nov 17, 2015ThioureidobutyronitrileTreatment of retinoblastoma.Innovation Pharmaceuticals, Inc.Designated
Nov 19, 2012MelphalanTreatment of retinoblastomaEyePoint Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.